LinkedIn Share

Biologics Analytical Testing for Confirming Drug Purity Prior to Release 


  • Biologics analytical testing is already underway in our GMP laboratory. For a biopharma company, analytical testing provides a critical part of the evidence demonstrating that a batch meets predefined quality requirements before release. 
  • The purity of a complex biological product cannot normally be established by single, universal measurement. Results must be derived from a coordinated panel of complementary methods. 

Biologics Analytical Testing in Drug Purity Confirmation 

Analytical method begins in an R&D laboratory, often with uncertainty. Scientists first identify the product’s critical quality attributes and define what the method must measure, at what level and with what degree of precision. An Analytical Target Profile can then guide the selection of appropriate analytical methods for biologics. Where an enhanced development approach is applied, Design of Experiments (DoE) can be used to evaluate interactions between method parameters and their impact on analytical procedure performance. For a chromatographic method, development may involve testing column chemistries, mobile-phase composition, pH, flow rate, temperature, gradient shape and detection settings. Analytical method optimization stage is where biologics analytical testing becomes tailored to the molecule.1

analytical chromatographic method -biologics analytical testing
Fig. 1. Graph demonstrating interparametric dependency in the development of an analytical chromatographic method using the DoE approach.1 

Then, analytical method moves into the quality control (QC) environment. Validation is conducted under an approved protocol and assesses characteristics appropriate to the procedure’s purpose, such as specificity or selectivity, accuracy, repeatability, intermediate precision, reportable range and quantitation limit.2 Statistical evaluation provide evidence that apparent reliability is not the result of chance. The objective is to demonstrate that the procedure remains fit for its intended use and robust under realistic operating conditions. Once implemented, the method becomes part of biologics quality control, supporting in-process decisions, stability monitoring and biologics release testing. In the QC of biologics, a passing result must also be traceable to the sample, analyst, instrument, calculation, reference standard and approved specification. 

Key Attributes of Biologics Purity Assessed 

Product-related impurities originate from the molecule itself. A therapeutic protein may aggregate into dimers or larger high-molecular-weight assemblies, undergo fragmentation, adopt an unintended conformation or accumulate chemically modified forms during production, purification, transport or storage. Oxidation, deamidation, clipping, disulfide-bond changes and other transformations can alter molecular behavior. Some variants remain active and may be considered product-related substances. Others may affect potency, stability, pharmacokinetics or immunogenicity and therefore need to be controlled as impurities. The boundary is product-specific and depends on structural, functional, nonclinical and clinical knowledge.3 

Process-related impurities come from the manufacturing environment rather than from the intended protein. They may include host cell proteins, residual host-cell DNA, leached Protein A, media components, enzymes, buffers, antifoam agents or other reagents introduced upstream or downstream. Endotoxins and microorganisms represent additional contamination risks that demand highly sensitive control. ICH Q6B formally distinguishes process-related impurities from product-related impurities and emphasizes that purity is generally method-dependent. For that reason, impurity testing biologics required coordinated investigation of several distinct impurity families.4 

Impurity type Impact on quality 
Aggregates Affect stability, biological activity, pharmacokinetics or immunogenicity 
Fragmented molecules Loss of structural integrity or altered activity 
Misfolded variants Reduce activity or expose unintended structural regions 
Charge variants May influence function or clearance 
 Glycosylation variants Influence stability, effector function and pharmacokinetics 
Host cell proteins Affect safety and stability, may interact with other proteins 
Residual host-cell DNA Primarily safety-related impurity requiring regulatory control  
Leached Protein A Indicate insufficient clearance or column-related contamination 
Tab. 1. Threats to the quality of a biological drug resulting from impurities.5 

Analytical Methods Used to Detect Impurities, Contaminants and Product Variants 

Depending on their intended purpose, analytical methods below require qualified equipment, characterized standards and analysts trained to recognize matrix interference.  

Drug Characterization and Release Testing Services

Comprehensive Drug Characterization

Drug Characterization / Comparability / Similarity
Method Panel
Physicochemical Analitycs
Protein concentration
ELISA, UV-VIS, HPLC-UV, HPLC-FLD
Identity Confirmation
Peptide Mapping, Western Blot
Molecular weight
Process-related impurities
ELISA, qPCR
Product-Related impurities
CE, SEC, SDS-PAGE, WCX
Glycosylation profile
HILIC-UHPLC with MS, RP-HPLC-MS
Monosaccharide
UHPLC-FLD
Sialic acid content
UHPLC-FLD
Site occupancy
UHPLC-MS
Oxidation, Deamidation and other
Peptide mapping, Mapping with MS
Glycation
UHPLC-FLD
Structural Analytics
Protein sequence confirmation
UHPLC-MS, HPLC-MS
Disulfide bridges identification
UHPLC-MS
Secondary structure
CD
Tertiary structure
CD
Free thiols
Ellman’s assay
Biological Analytics
Cell-based assays
CDC
ADCP
Apoptosis
ADCC reporter and PBMC-based
Protein – protein interaction
SPR FcR Binding, FCRN, CD32, CD16
ELISA Test
Flow cytometry

For process-related impurities, biologics analytical testing begins with methods designed to find very small amounts of unwanted material in a comparatively large amount of therapeutic protein.  

Host cell proteins are commonly quantified by sandwich ELISA. In this assay, antibodies immobilized on a microplate capture a broad population of residual proteins, while a second labelled antibody generates a concentration-dependent signal. A separate, highly specific ELISA may be used when the target is an individual residual protein or leached Protein A. At minimum spike recovery, standard-curve performance and replicate variability are assessed against predefined acceptance criteria before a result is accepted,6 

Residual host-cell DNA may be measured by real-time quantitative PCR (qPCR) using a Light Cycler 480 or by the PicoGreen assay using a HIDEX Sense. Real-time PCR amplifies a selected host-cell DNA sequence and monitors fluorescence during each amplification cycle, allowing sensitive, sequence-specific quantification against a standard curve. PicoGreen instead uses a fluorescent dye that binds double-stranded DNA, providing a broader estimate of total residual DNA without sequence-specific amplification. Extraction recovery and appropriate sample dilution are important for both approaches, while inhibition controls are particularly relevant to qPCR-based methods.7 

Endotoxin is assessed through the LAL Assay. Mabion can apply Gel Clot, Turbidimetric and Chromogenic formats:  

  • LAL Gel Clot assay records formation of a gel at a defined endotoxin level.  
  • LAL Turbidimetric assay measures increasing cloudiness during the reaction.  
  • LAL Chromogenic assay quantifies colour generated by cleavage of a synthetic substrate.  

Product-specific inhibition or enhancement studies and positive product controls are essential because a biologic’s formulation can influence the reaction.8 

Mycoplasma detection is performed using a validated qPCR assay targeting conserved microbial DNA sequences. Extraction controls, amplification controls and appropriately selected positive and negative controls help demonstrate that a negative result reflects the absence of detectable contamination rather than assay inhibition.9 

Fig. 2. Mabion QC expert conducting a microscopic analysis. 

Product-related impurities require separation technologies that reveal different dimensions of molecular heterogeneity.  

Capillary electrophoresis, particularly CE-SDS, places denatured protein species in a narrow capillary and separates them under an electric field. Because SDS gives proteins a broadly consistent charge-to-mass relationship, migration is driven mainly by molecular size. Non-reducing conditions can assess intact or partially assembled molecules, while reducing conditions resolve subunits such as antibody heavy and light chains. Qualified Cesi 8000 Plus system equipped with UV or laser-induced fluorescence (LIF) detection provide high-resolution electropherograms, but reliable results still depend on careful sample denaturation, reduction, alkylation, injection and integration.10,11 

Size Exclusion Chromatography – High-Performance Liquid Chromatography (SEC-HPLC) answers a different question. The column contains porous particles: large aggregates enter fewer pores and generally elute earlier, while monomeric and smaller species spend more time within the stationary phase. This makes SEC-HPLC a central method for quantifying monomer, high-molecular-weight forms and, where resolution permits, low-molecular-weight fragments. At Mabion, SEC methods are performed using product-specific chromatographic columns selected according to the characteristics of the molecule and the validated analytical procedure. Analysts must control mobile-phase composition, column condition, sample concentration and non-specific interactions, as these factors can affect peak shape, retention behavior, and the apparent distribution of monomer and aggregates.12,13 

Weak cation-exchange chromatography (WCX-HPLC), separates the molecule according to surface charge. Under selected pH conditions, the protein interacts with negatively charged groups on the stationary phase and is eluted using a salt, pH or combined gradient. Acidic, main and basic variants appear as separate peaks whose relative abundance can be compared across batches or against acceptance criteria. Mabion’s analytical platform includes WCX-HPLC and other ion-exchange approaches for charge profiling.14,15 

SDS-PAGE provides an established orthogonal view of molecular size and integrity. After electrophoresis through a polyacrylamide gel, separated bands are stained and compared with molecular-weight markers and reference material. Although it is generally less precise for quantitative release measurements than CE-SDS, reducing and non-reducing SDS-PAGE can expose unexpected fragments, unassembled chains or additional protein bands that warrant investigation.16 

Product variants become especially important when post-translational modifications influence the molecule’s biological behaviour.  

HILIC-UHPLC is used to establish a glycosylation profile by separating glycans according to their hydrophilic interactions with the stationary phase. Sample preparation is critical. Incomplete glycan release, inconsistent labelling or selective loss of individual structures can shift the apparent profile before the sample reaches the instrument. In a typical workflow, N-linked glycans are enzymatically released from the protein, fluorescently labelled and injected into a Vanquish UHPLC. The resulting peaks are assigned using standards, retention libraries, enzymatic digestion or mass-spectrometric confirmation, depending on the method’s purpose.17 

Peptide mapping with MS moves the analysis closer to single-residue resolution. Reduced peptide mapping is commonly used for sequence confirmation and post-translational modifications (PTMs). Disulfide-bond connectivity requires a dedicated non-reduced mapping workflow in which native disulfide linkages are preserved for analysis.. Reduced peptide mapping is commonly used for sequence confirmation and PTM assessment. Disulfide-bond connectivity requires a dedicated non-reduced mapping workflow in which native disulfide linkages are preserved for analysis. The method requires high-resolution LC-MS equipment such as Q-Exactive Plus mass spectrometer, controlled sample preparation, qualified data-processing procedures and scientists trained to distinguish genuine molecular changes from digestion artefacts, carryover, in-source fragmentation or software misassignment.18-21 

UHPLC-FLD can quantify sialic acid content after the relevant residues have been released from the molecule and derivatized with a fluorescent label. Separation by UHPLC and detection by fluorescence provide sensitivity for comparing sialic-acid species and total content, but hydrolysis conditions must be controlled because sialic acids are chemically labile. 

UHPLC-MS is used for glycosylation site occupancy analysis. After enzymatic digestion, glycosylated and non-glycosylated peptides associated with a particular site can be detected and compared, sometimes with complementary deglycosylation strategies. Because different glycopeptides may ionize with different efficiencies, quantitation must be supported by an appropriately validated analytical and data-processing strategy.22 

Linking Purity Testing with Critical Quality Attributes 

The strength of a multi-method analytical strategy lies in the integration of results from complementary technologies and their interpretation in the context of product and process knowledge. A peak is not interpreted in isolation. It is evaluated against system-suitability criteria, reference material, historical trends, orthogonal results and the known behavior of the product. 

Biologics purity analysis supports the broader assessment of critical quality attributes through monitoring of product variants, process-related impurities and other relevant quality indicators. A rising HCP result may trigger review of harvest conditions, clarification performance or chromatography loading. An increase in aggregates may point toward low-pH exposure, concentration steps, shear, freeze–thaw handling or storage conditions. Shifts in charge variants or glycosylation can lead scientists back to cell-culture pH, temperature, feed strategy or process duration. None of these signals proves causation alone, but together they create a map of where an investigation should begin. In this way, biologics analytical testing become a continuous source of process knowledge, linking the analytical laboratory with upstream development, downstream purification, manufacturing, stability and quality assurance. 

GMP and Regulatory Expectations for Biologics Analytical Testing 

Regulators expect a scientifically justified, product-specific control strategy. Regulatory guidelines for biological products emphasize a scientifically justified, product-specific control strategy that addresses relevant product-related variants and process-related impurities. The key assumptions of analytical testing are contained in the following documents: 

  • ICH Q2(R2) guideline covers analytical method validation and applies directly to analytical procedures used for release testing and stability studies.23 
  • ICH Q6B guideline refers for characterization of physicochemical properties, biological activity, purity and impurities and recognizes the division between process-related and product-related impurities. It also emphasizes that a combination of orthogonal methods is usually needed for regulatory approval.5 
  • ICH Q14 guideline frames analytical development as a lifecycle activity built around product attributes, appropriate technology, performance characteristics and a documented control strategy.24 

Mabion has operated within a GMP-certified environment since 2012. High-quality biologics analytical testing is supported through controlled method development and transfer, method validations, qualified instruments, calibrated laboratory equipment, documented analyst training and predefined system-suitability requirements. Reference standards and critical reagents are qualified for their intended use, while sample receipt, preparation, analysis and storage remain traceable. Key laboratory and quality processes are supported by electronic systems, including LIMS and eQMS, while electronic and paper records are managed in accordance with applicable data-integrity requirements. Method performance is reviewed throughout the lifecycle, because a validated method can lose suitability as equipment, reagents, manufacturing processes or product knowledge evolve. This quality system is what enables GMP release testing to provide evidence that can withstand regulatory review. 

Ensuring Release Readiness Through Reliable Analytical Data 

A passing purity result is only one component of release readiness. In biologics analytical testing, QC teams review raw data, chromatograms, electropherograms, amplification curves, plate results, calculations, system suitability, instrument status and compliance with approved methods. The broader batch release process also considers manufacturing documentation, results from in-process testing and other process controls, microbiological results, stability commitments, reference and retention samples, deviations, changes and other quality-related information that may affect the approved control strategy. Final release readiness therefore depends on the combined assessment of analytical, manufacturing and quality-system data in accordance with defined responsibilities within the pharmaceutical quality system.25 

High-quality QC work is not only about obtaining results that meet acceptance criteria, but also about understanding what those results tell us about the product. This is particularly important in biologics purity testing, where no single method provides the full picture and different analytical techniques need to complement each other. At Mabion, we combine this scientific understanding with GMP discipline to provide reliable data that support quality decisions.

Amanda Jabłońska, Physical and Biological Analysis Division Manager

The analytical panel described by Mabion is effective because it does not attempt to compress biological-drug purity into one convenient number. Biologics analytical testing applied by trained teams create a reliable framework from process development to final release. For manufacturers, that framework protects strict timelines and regulatory submissions. 

Conclusion 

The analytical panel described by Mabion reflects the multidimensional nature of biologics purity by combining complementary methods that assess different product attributes and impurity classes. When applied within a controlled GMP environment by trained analytical teams, these methods provide a reliable framework for generating and interpreting quality data from process development through routine testing and release. For manufacturers, such an analytical strategy supports well-informed quality decisions and robust regulatory submissions. 

FAQ

Biologics analytical testing uses complementary physicochemical, biochemical, molecular, and microbiological methods to evaluate the quality of a biological product. Because biologics are structurally complex, multiple analytical techniques are typically required to assess purity, product variants, process-related impurities, and other relevant quality attributes.
Biologics purity testing can use methods such as CE-SDS, SEC-HPLC, WCX-HPLC, SDS-PAGE, ELISA, qPCR, HILIC-UHPLC, and LC-MS-based techniques. These methods provide complementary information about aggregates, fragments, charge variants, host-cell proteins, residual DNA, glycosylation, and other product or process characteristics.
No single analytical method can fully characterize the purity of a complex biological product. A combination of orthogonal methods allows different impurity classes and molecular attributes to be assessed, providing a more complete picture of product quality and supporting the evaluation of critical quality attributes.
Validated or appropriately controlled analytical methods generate traceable quality data that support batch-release decisions. GMP release testing also requires review of raw analytical data, system suitability, instrument status, manufacturing documentation, microbiological results, deviations, and other information relevant to the approved control strategy.

Prepared by:

Jakub Knurek
Jakub Knurek

Marketing Specialist

j.knurek@mabion.eu
Amanda Jabłońska
Amanda Jabłońska

Physicochemical and Biological Testing Division Manager

a.jablonska@mabion.eu

References

  1. Passerine BFG, Breitkreitz MC. Important Aspects of the Design of Experiments and Data Treatment in the Analytical Quality by Design Framework for Chromatographic Method Development. Molecules. 2024; 29(24): 6057. 
  2. EMA. ICH Q2(R2) Validation of analytical procedures. 2026. 
  3. Wang D, Wynne C, Gu F, Becker C, Zhao J, Mueller HM, Li H, Shameem M, Liu YH. Characterization of drug-product-related impurities and variants of a therapeutic monoclonal antibody by higher energy C-trap dissociation mass spectrometry. Anal Chem. 2015; 87(2): 914-921. 
  4. Larivière L, Krüger JE, von Hirschheydt T, Schlothauer T, Bray-French K, Bader M, Runza V. End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations. Int J Pharm X. 2023; 5: 100157. 
  5. EMA. ICH Q6B Specifications: test procedures and acceptance criteria for biotechnological/biological products. 1999. 
  6. Falkenberg H, Waldera-Lupa DM, Vanderlaan M, Schwab T, Krapfenbauer K, Studts JM, Flad T, Waerner T. Mass spectrometric evaluation of upstream and downstream process influences on host cell protein patterns in biopharmaceutical products. Biotechnol Prog. 2019; 35(3): e2788. 
  7. Zheng W, Jiang L, Lei Q, Yang J, Gao X, Wang W, Zhang Y, Kong T, Chen Q, Li G. Development and Validation of Quantitative Real-Time PCR for the Detection of Residual CHO Host Cell DNA and Optimization of Sample Pretreatment Method in Biopharmaceutical Products. Biol Proced Online. 2019; 21: 17. 
  8. Thota P, Kumar P, Teotia AK, Kaushik A, Rajpali R, Pandey M, Dahiya M, Kalaiselvan V. Study of LAL and Recombinant Cascade Reagents Methods for Bacterial Endotoxin Testing in Pharmaceutical Products. PDA J Pharm Sci Technol. 2026; 80(3): 288-297. 
  9. Carrillo-Ávila JA, de la Fuente A, Aguilar-Quesada R, Ligero G, Del Río-Ortiz JM, Catalina P. Development and Evaluation of a New qPCR Assay for the Detection of Mycoplasma in Cell Cultures. Curr Issues Mol Biol. 2023; 45(8): 6903-6915. 
  10. Li M, Yu C, Wang W, Wu G, Wang L. Interlaboratory method validation of capillary electrophoresis sodium dodecyl sulfate (CE-SDS) methodology for analysis of mAbs. Electrophoresis. 2021; 42(19): 1900-1913. 
  11. Cernosek T, Dalphin M, Sakowski J, Behrens S, Wunderli P. Application of Analytical Quality by Design to the development and validation of reduced and non-reduced capillary electrophoresis analytical procedures for mAb purity determination. J Pharm Biomed Anal. 2024; 249: 116386. 
  12. Schrag D, Corbier M, Raimondi S. Size exclusion-high-performance liquid chromatography (SEC-HPLC). Methods Mol Biol. 2014; 1131: 507-512. 
  13. Pan H, Chen K, Pulisic M, Apostol I, Huang G. Quantitation of soluble aggregates in recombinant monoclonal antibody cell culture by pH-gradient protein A chromatography. Anal Biochem. 2009; 388(2): 273-278. 
  14. Ponniah G, Nowak C, Neill A, Liu H. Characterization of charge variants of a monoclonal antibody using weak anion exchange chromatography at subunit levels. Anal Biochem. 2017; 520: 49-57. 
  15. Liu H, Ren W, Zong L, Zhang J, Wang Y. Characterization of recombinant monoclonal antibody charge variants using WCX chromatography, icIEF and LC-MS/MS. Anal Biochem. 2019; 564-565: 1-12. 
  16. Metzendorf NG, Petersen I, Hultqvist G. Enhancing therapeutic antibody profiling: orthogonal strategies for stability and quality assessment. Front Pharmacol. 2025; 16: 1667210. 
  17. Singh SK, Lee KH. Characterization of Monoclonal Antibody Glycan Heterogeneity Using Hydrophilic Interaction Liquid Chromatography-Mass Spectrometry. Front Bioeng Biotechnol. 2022; 9: 805788. 
  18. Dada OO, Zhao Y, Jaya N, Salas-Solano O. High-Resolution Capillary Zone Electrophoresis with Mass Spectrometry Peptide Mapping of Therapeutic Proteins: Peptide Recovery and Post-translational Modification Analysis in Monoclonal Antibodies and Antibody-Drug Conjugates. Anal Chem. 2017; 89(21): 11236-11242. 
  19. Xu C, Khanal S, Pierson NA, Quiroz J, Kochert B, Yang X, Wylie D, Strulson CA. Development, validation, and implementation of a robust and quality control-friendly focused peptide mapping method for monitoring oxidation of co-formulated monoclonal antibodies. Anal Bioanal Chem. 2022; 414(29-30): 8317-8330. 
  20. Yang F, Zhang J, Buettner A, Vosika E, Sadek M, Hao Z, Reusch D, Koenig M, Chan W, Bathke A, Pallat H, Lundin V, Kepert JF, Bulau P, Deperalta G, Yu C, Beardsley R, Camilli T, Harris R, Stults J. Mass spectrometry-based multi-attribute method in protein therapeutics product quality monitoring and quality control. MAbs. 2023; 15(1): 2197668. 
  21. Dobrowolski M, Urbaniak M, Pietrucha T. Peptide Mapping for Sequence Confirmation of Therapeutic Proteins and Recombinant Vaccine Antigens by High-Resolution Mass Spectrometry: Software Limitations, Pitfalls, and Lessons Learned. Int J Mol Sci. 2025; 26(20): 9962. 
  22. Yang N, Goonatilleke E, Park D, Song T, Fan G, Lebrilla CB. Quantitation of Site-Specific Glycosylation in Manufactured Recombinant Monoclonal Antibody Drugs. Anal Chem. 2016; 88(14): 7091-7100. 
  23. EMA. ICH Q2(R2) Validation of analytical procedures. 2023. 
  24. EMA. ICH Q14 Analytical procedure development. 2023. 
  25. Jabłońska A, Knurek J. Release Testing for Biologics – Regulatory Requirements for GMP Compliance. Mabion Science Hub. 2025. 

Related resources